免疫治疗试验中基于生物标志物的给药方案优化设计
针对免疫治疗中剂量与给药方案影响疗效的问题,提出基于生物标志物亚组的剂量-方案优化策略,利用效用函数权衡风险与获益,并建立联合模型同时评估免疫反应、毒性和疗效。模拟研究显示该设计具有理想的操作特性,能有效指导剂量-方案优化。
要点
- 按生物标志物亚组分别优化剂量与给药方案,利用效用函数权衡风险与获益。
- 联合建模框架同时评估免疫反应、毒性和疗效,实现结局类型与患者亚组间信息共享。
- 采用简约而灵活的模型应对早期试验常见的小样本挑战,模拟研究显示理想操作特性。
核心结论
- 提出的基于生物标志物的剂量-方案优化设计在模拟研究中展现出理想的操作特性,能有效指导剂量-方案优化。
研究设计与样本
- 提出一种基于诱出效用函数的剂量-方案优化策略,针对每个生物标志物定义的亚组分别进行优化。
- 建立联合建模框架,同时评估免疫反应、毒性和疗效,实现不同结局类型与患者亚组间的信息共享。
- 采用简约而灵活的模型,专门应对早期试验中常见的小样本挑战。
主要发现
- 模拟研究表明,所提出的设计达到了理想的操作特性,并有效指导剂量-方案优化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In immunotherapy, both the dose and the schedule of drug administration can significantly influence therapeutic effects by modulating immune system activation. Incorporating immune response measures into clinical trial designs offers an opportunity to enhance decision-making by leveraging their close association with therapeutic efficacy and toxicity. Motivated by settings where biomarker data indicate improved efficacy in biomarker-positive patients, we propose a dose-schedule optimization strategy tailored to each biomarker-defined subgroup, based on elicited utility functions that capture risk-benefit tradeoffs. We introduce a joint modeling framework that simultaneously evaluates immune response, toxicity, and efficacy, enabling information sharing across outcome types and patient subgroups. Our approach utilizes parsimonious yet flexible models designed specifically to address challenges due to small sample sizes commonly encountered in early-phase trials. Simulation studies demonstrate that the proposed design achieves desirable operating characteristics and effectively informs dose-schedule optimization.
引用
- Qiu Y, Han Y, Guo B, et al. A Biomarker-Based Dose-Schedule Optimization Design for Immunotherapy Trials. Stat Med. 2026. PMID: 41572569. doi:10.1002/sim.70357
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。